The INNOVATION study is a randomized clinical trial assessing the efficacy of adding pertuzumab to standard chemotherapy plus trastuzumab in patients with HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma. Patients were randomized to receive chemotherapy with trastuzumab alone or in combination with pertuzumab. The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), and safety.

The results showed that the addition of pertuzumab did not significantly improve OS compared to trastuzumab alone. Similarly, no meaningful differences were observed in PFS or ORR between the treatment arms. However, the pertuzumab arm was associated with increased toxicity. These findings were presented at the 2024 ASCO Gastrointestinal Cancers Symposium and discussed by experts including Dr. Amol Akhade and Dr. Anna Dorothea Wagner, highlighting the ongoing challenges in optimizing HER2-targeted strategies in upper GI malignancies.